This company is no longer active
SBTX Stock Overview
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Silverback Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.87 |
| 52 Week High | US$8.97 |
| 52 Week Low | US$2.80 |
| Beta | 0 |
| 1 Month Change | 11.81% |
| 3 Month Change | 16.70% |
| 1 Year Change | -30.12% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.52% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Silverback Therapeutics' (NASDAQ:SBTX) Cash Burn Situation
Jul 13
Companies Like Silverback Therapeutics (NASDAQ:SBTX) Are In A Position To Invest In Growth
Aug 30Silverback Therapeutics (NASDAQ:SBTX) Is In A Good Position To Deliver On Growth Plans
May 15Have Insiders Been Buying Silverback Therapeutics, Inc. (NASDAQ:SBTX) Shares This Year?
Mar 04Silverback Therapeutics is a buy at Goldman Sachs on unique therapy platform
Dec 30Shareholder Returns
| SBTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | 3.4% | 1.6% |
| 1Y | -30.1% | 3.8% | 25.1% |
Return vs Industry: SBTX underperformed the US Biotechs industry which returned -18% over the past year.
Return vs Market: SBTX underperformed the US Market which returned -25.3% over the past year.
Price Volatility
| SBTX volatility | |
|---|---|
| SBTX Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SBTX has not had significant price volatility in the past 3 months.
Volatility Over Time: SBTX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 92 | Jeffrey Pepe | www.silverbacktx.com |
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Silverback Therapeutics, Inc. Fundamentals Summary
| SBTX fundamental statistics | |
|---|---|
| Market cap | US$211.66m |
| Earnings (TTM) | -US$85.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs SBTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$85.71m |
| Earnings | -US$85.71m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SBTX perform over the long term?
See historical performance and comparison